Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Agios Pharmaceuticals Inc AGIO

Healthcare Biotechnology
Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering transformative therapies for patients living with rare diseases. It markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its genetically defined... see more

Recent & Breaking News (NDAQ:AGIO)

FDA Accepts New Drug Application and Grants Priority Review for Ivosidenib in Relapsed or Refractory AML with an IDH1 Mutation

GlobeNewswire February 15, 2018

Agios Pharmaceuticals, Inc. to Host Earnings Call

Accesswire February 14, 2018

Agios to Webcast Conference Call of Fourth Quarter and Full Year 2017 Financial Results on February 14, 2018

GlobeNewswire January 31, 2018

Agios Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares

GlobeNewswire January 23, 2018

A Survey Of Celgene's M&A Strategy

Benzinga.com  January 19, 2018

Agios Announces Pricing of $475 Million Public Offering of Common Stock

GlobeNewswire January 18, 2018

Agios Announces Proposed Offering of Common Stock

GlobeNewswire January 17, 2018

Newman Ferrara LLP Announces Corporate Governance Investigation of Agios Pharmaceuticals Inc. - AGIO

Business Wire January 8, 2018

Agios Outlines Key 2018 Priorities Expanding Clinical and Research Programs to Drive Long Term Value

GlobeNewswire January 8, 2018

Agios to Present at the 36th Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2018

GlobeNewswire January 2, 2018

Agios Submits New Drug Application to the FDA for Ivosidenib for the Treatment of Patients with Relapsed/Refractory AML and an IDH1 Mutation

GlobeNewswire December 26, 2017

Data from Phase 1 Studies of Ivosidenib or Enasidenib in Combination with Full Doses of Standard of Care Chemotherapy Demonstrate Tolerability and Preliminary Clinical Activity in Newly Diagnosed AML Patients With an IDH Mutation

GlobeNewswire December 11, 2017

New Data from Ivosidenib Phase 1 Dose-Escalation and Expansion Trial Demonstrate Durable Responses in Patients with IDH1m Relapsed or Refractory AML

GlobeNewswire December 11, 2017

Agios Presents Updated Data from DRIVE PK Study Demonstrating AG-348 is Well-Tolerated and Results in Clinically Relevant, Rapid and Sustained Hemoglobin Increases in Patients with Pyruvate Kinase Deficiency

GlobeNewswire December 10, 2017

Agios Appoints Jacqualyn Fouse, Ph.D., to the Board of Directors

GlobeNewswire December 5, 2017

Agios Presents Updated Phase 1 Data from Dose Expansion Cohort of Ivosidenib (AG-120) in Patients with IDH1 Mutant Positive Glioma

GlobeNewswire November 17, 2017

Agios to Present New Data from PKR and IDH Programs at the 2017 ASH Annual Meeting

GlobeNewswire November 1, 2017

Agios Reports Third Quarter 2017 Financial Results

GlobeNewswire November 1, 2017

Agios Pharmaceuticals, Inc. to Host Earnings Call

Accesswire November 1, 2017

Agios to Present at the 26th Annual Credit Suisse Healthcare Conference Tuesday, November 7, 2017

GlobeNewswire October 31, 2017